Treatment with the experimental therapy nerandomilast appears to reduce the risk of death in people with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF), according to a new analysis of clinical trial data presented by the therapy’s developer, Boehringer Ingelheim. “The new pooled data zoom in on nerandomilast’s potential as monotherapy, pairing efficacy with […] The post Nerandomilast appears to reduce risk of death in IPF, PPF: trial data appeared first o...
